In Silico Driven Design and Synthesis of Rhodanine Derivatives as Novel Antibacterials Targeting the Enoyl Reductase InhA

Journal of Medicinal Chemistry

Volumn 59, Issue 24, 2016, Pages 10917-10928

  Slepikas, Liudas ^a,b   Chiriano, Gianpaolo ^a   Perozzo, Remo ^a   Tardy, Sébastien ^a   Kranjc, Agata ^a   Patthey Vuadens, Ophélie ^a   Ouertatani Sakouhi, Hajer ^c   Kicka, Sébastien ^a   Harrison, Christopher F ^d   Scrignari, Tiziana ^a   Perron, Karl ^a   Hilbi, Hubert ^d,e   Soldati, Thierry ^a   Cosson, Pierre ^c   Tarasevicius, Eduardas ^b   Scapozza, Leonardo ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b LITHUANIAN UNIVERSITY OF HEALTH SCIENCES   (Lithuania)

^c CMU   (Switzerland)

^d UNIVERSITY OF MUNICH   (Germany)

^e UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

2 [(5Z) 4 OXO 5 (4 PROPYLBENZYLIDENE 4 OXO 2 THIOXO 1,3 THIAZOLIDIN 3 YL)] 3 (1H INDOL 3YL)PROPANOIC ACID; 2 [(5Z) 5 [(4 BIS (2 CHLOROETHYL)AMINO]BENZYLIDENE 4 OXO 2 THIOXO 1,3 THIAZOLIDIN 3 YL)] 3 (1H INDOL 3YL)PROPANOIC ACID; 2 [(5Z) 5 [4 (DIETHYLAMINO)BENZYLIDENE] 4 OXO 2 THIOXO 1,3 THIAZOLIDIN 3 YL] 3 (1H INDOL 3YL)PROPANOIC ACID; 2 [(5Z) 5 [4 (DIETHYLAMINO)BENZYLIDENE] 4 OXO 2 THIOXO 1,3 THIAZOLIDIN 3 YL] 4 METHYLPENTANOIC ACID; 2 [(5Z) 5 [4 (DIMETHYLAMINO)BENZYLIDENE] 4 OXO 2 THIOXO 1,3 THIAZOLIDIN 3 YL] 3 (1H INDOL 3 YL)PROPANOIC ACID; 2 [(5Z) 5 [4 (DIMETHYLAMINO)BENZYLIDENE] 4 OXO 2 THIOXO 1,3 THIAZOLIDIN 3 YL] 3 METHYLPENTANOIC ACID; 2 [(5Z) 5 [4 (DIMETHYLAMINO)BENZYLIDENE] 4 OXO 2 THIOXO 1,3 THIAZOLIDIN 3 YL] 4 (METHYLSELENYL)BUTANOIC ACID; 2 [(5Z) 5 [4 (DIMETHYLAMINO)BENZYLIDENE] 4 OXO 2 THIOXO 1,3 THIAZOLIDIN 3 YL] 4 (METHYLSULFANYL)BUTANOIC ACID; 2 [(5Z) 5 [4 (DIMETHYLAMINO)BENZYLIDENE] 4 OXO 2 THIOXO 1,3 THIAZOLIDIN 3 YL] 4 METHYLPENTANOIC ACID; 2 [(5Z) 5 [4 (DIMETHYLAMINO)BENZYLIDENE] 4 OXO 2 THIOXO 1,3 THIAZOLIDIN 3 YL]BUTANEDOIC ACID; 2 [(5Z) 5 [4 (DIMETHYLAMINO)BENZYLIDENE] 4 OXO 2 THIOXO 1,3 THIAZOLIDIN 3 YL]HEXANOIC ACID; 2 [(5Z) 5 [4 (DIMETHYLAMINO)BENZYLIDENE] 4 OXO 2 THIOXO 1,3 THIAZOLIDIN 3 YL]PENTANOIC ACID; 2 [(5Z) 5 [4 (METHYLSULFANYL)BENZYLIDENE] 4 OXO 2 THIOXO 1,3 THIAZOLIDIN 3 YL]METHYLPENTANOIC ACID; 2 [(5Z) 5 [4 FLUOROBENZYLIDENE] 4 OXO 2 THIOXO 1,3 THIAZOLIDIN 3 YL] 4 METHYLPENTANOIC ACID; 2 [(5Z) 5 [4 PROPYLBENZYLIDENE] 4 OXO 2 THIOXO 1,3 THIAZOLIDIN 3 YL] 3 (1H INDOL 3YL)PROPANOIC ACID; 2 [(5Z) 5 [4 [BIS(2 CHLOROETHYL)AMINO]BENZYLIDENE] 4 OXO 2 THIOXO 1,3 THIAZOLIDIN 3 YL] 3 (1H INDOL 3YL)PROPANOIC ACID; 2 [(5Z) 5 [[4 (DIMETHYLAMINO)NAPTHALENE 1 YL]METHYLIDENE] 4 OXO 2 THIOXO 1,3 THIAZOLIDIN 3 YL]HEXANOIC ACID; 2 [(5Z) 5 [[4 (DIMETHYLAMINO)NAPTHALENE 1 YL]METHYLIDENE] 4 OXO 2 THIOXO 1,3 THIAZOLIDIN 3 YL]PENTANOIC ACID; 3 (1H INDOL 3 YL) 2 [(5Z) 5 [[4 (DIMETHYLAMINO)NAPHTHALENE 1 YL]METHYLIDENE] 4 OXO 2 THIOXO 1,3 THIAZOLIDIN 3 YL]PROPANOIC ACID; 3 [(5Z) 5 [4 (DIMETHYLAMINO)BENZYLIDENE] 4 OXO 2 THIOXO 1,3 THIAZOLIDIN 3 YL]PROPANOIC ACID; 4 METHYL 2 [(5Z) 5 [[4 (DIMETHYLAMINO)NAPHTHALENE 1YL]METHYLIDENE] 4 OXO 2 THIOXO 1,3 THIAZOLIDIN 3 YL]PENTANOIC ACID; 4 THIAZOLIDINONE DERIVATIVE; ANTIBIOTIC AGENT; N [(5Z) 5 [4 (DIMETHYLAMINO)BENZYLIDENE] 4 OXO 2 THIOXO 1,3 THIAZOLIDIN 3 YL] 3 METHYLBUTANAMIDE; OXIDOREDUCTASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; [(5Z) 5 [4 (DIMETHYLAMINO)BENZYLIDENE] 4 OXO 2 THIOXO 1,3 THIAZOLIDIN 3 YL] 3 METHYLBUTANOIC ACID; [(5Z) 5 [4 (DIMETHYLAMINO)BENZYLIDENE] 4 OXO 2 THIOXO 1,3 THIAZOLIDIN 3 YL]BUTANOIC ACID; [(5Z) 5 [4 (DIMETHYLAMINO)BENZYLIDENE] 4 OXO 2 THIOXO 1,3 THIAZOLIDIN 3 YL]PROPANOIC ACID; [3 METHYL 1 [(5Z) 5 [[4 (DIMETHYLAMINO)NAPHTHALENE 1 YL]METHYLIDENE] 4 OXO 2 THIOXO 1,3 THIAZOLIDIN 3 YL] 3 METHYLBUTYL]PHOSPHONIC ACID; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; INHA PROTEIN, MYCOBACTERIUM; RHODANINE;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL VIRULENCE; CARBON NUCLEAR MAGNETIC RESONANCE; COMPUTER MODEL; DRUG DESIGN; DRUG SCREENING; DRUG SYNTHESIS; DRUG TARGETING; ENTEROCOCCUS FAECALIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROGEN BOND; HYDROPHOBICITY; IC50; KNOEVENAGEL CONDENSATION; LEGIONELLA PNEUMOPHILA; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR DOCKING; MYCOBACTERIUM MARINUM; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; PROTON TRANSPORT; PSEUDOMONAS AERUGINOSA; STRUCTURE ACTIVITY RELATION; THIN LAYER CHROMATOGRAPHY; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; ISOLATION AND PURIFICATION; METABOLISM; MICROBIAL SENSITIVITY TEST; MOLECULAR MODEL; SYNTHESIS;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; ENTEROCOCCUS FAECALIS; LEGIONELLA PNEUMOPHILA; MICROBIAL SENSITIVITY TESTS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; MYCOBACTERIUM MARINUM; OXIDOREDUCTASES; PSEUDOMONAS AERUGINOSA; RHODANINE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 85007197720     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b01620     Document Type: Article

References (42)

1. Antimicrobial Resistance: Global Report on Surveillance (In IRIS); World Health Organization: Geneva, 2014; p xxii, 232 pp.
2. Goldberg, D. E.; Siliciano, R. F.; Jacobs, W. R., Jr. Outwitting evolution: fighting drug-resistant TB, malaria, and HIV Cell 2012, 148, 1271-1283 10.1016/j.cell.2012.02.021
3. Zhang, Y. M.; Lu, Y. J.; Rock, C. O. The reductase steps of the type II fatty acid synthase as antimicrobial targets Lipids 2004, 39, 1055-1060 10.1007/s11745-004-1330-3
4. Rawat, R.; Whitty, A.; Tonge, P. J. The isoniazid-NAD adduct is a slow, tight-binding inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase: adduct affinity and drug resistance Proc. Natl. Acad. Sci. U. S. A. 2003, 100, 13881-13886 10.1073/pnas.2235848100
5. Ando, H.; Miyoshi-Akiyama, T.; Watanabe, S.; Kirikae, T. A silent mutation in mabA confers isoniazid resistance on Mycobacterium tuberculosis Mol. Microbiol. 2014, 91, 538-547 10.1111/mmi.12476
6. Cade, C. E.; Dlouhy, A. C.; Medzihradszky, K. F.; Salas-Castillo, S. P.; Ghiladi, R. A. Isoniazid-resistance conferring mutations in Mycobacterium tuberculosis KatG: catalase, peroxidase, and INH-NADH adduct formation activities Protein Sci. 2010, 19, 458-474 10.1002/pro.324
7. Sullivan, T. J.; Truglio, J. J.; Boyne, M. E.; Novichenok, P.; Zhang, X.; Stratton, C. F.; Li, H. J.; Kaur, T.; Amin, A.; Johnson, F.; Slayden, R. A.; Kisker, C.; Tonge, P. J. High affinity InhA inhibitors with activity against drug-resistant strains of Mycobacterium tuberculosis ACS Chem. Biol. 2006, 1, 43-53 10.1021/cb0500042
8. Kinjo, T.; Koseki, Y.; Kobayashi, M.; Yamada, A.; Morita, K.; Yamaguchi, K.; Tsurusawa, R.; Gulten, G.; Komatsu, H.; Sakamoto, H.; Sacchettini, J. C.; Kitamura, M.; Aoki, S. Identification of compounds with potential antibacterial activity against Mycobacterium through structure-based drug screening J. Chem. Inf. Model. 2013, 53, 1200-1212 10.1021/ci300571n
9. He, X.; Alian, A.; Stroud, R.; Ortiz de Montellano, P. R. Pyrrolidine carboxamides as a novel class of inhibitors of enoyl acyl carrier protein reductase from Mycobacterium tuberculosis J. Med. Chem. 2006, 49, 6308-6323 10.1021/jm060715y
10. Broussy, S.; Bernardes-Genisson, V.; Quemard, A.; Meunier, B.; Bernadou, J. The first chemical synthesis of the core structure of the benzoylhydrazine-NAD adduct, a competitive inhibitor of the Mycobacterium tuberculosis enoyl reductase J. Org. Chem. 2005, 70, 10502-10510 10.1021/jo051901z
11. Delaine, T.; Bernardes-Genisson, V.; Meunier, B.; Bernadou, J. Synthesis of the isonicotinoylnicotinamide scaffolds of the naturally occurring isoniazid-NAD(P) adducts J. Org. Chem. 2007, 72, 675-678 10.1021/jo062100e
12. Hartkoorn, R. C.; Sala, C.; Neres, J.; Pojer, F.; Magnet, S.; Mukherjee, R.; Uplekar, S.; Boy-Rottger, S.; Altmann, K. H.; Cole, S. T. Towards a new tuberculosis drug: pyridomycin-nature's isoniazid EMBO Mol. Med. 2012, 4, 1032-1042 10.1002/emmm.201201689
13. Horlacher, O. P.; Hartkoorn, R. C.; Cole, S. T.; Altmann, K. H. Synthesis and antimycobacterial activity of 2,1′-dihydropyridomycins ACS Med. Chem. Lett. 2013, 4, 264-268 10.1021/ml300385q
14. Carlson, E. E.; May, J. F.; Kiessling, L. L. Chemical probes of UDP-galactopyranose mutase Chem. Biol. 2006, 13, 825-837 10.1016/j.chembiol.2006.06.007
15. Sim, M. M.; Ng, S. B.; Buss, A. D.; Crasta, S. C.; Goh, K. L.; Lee, S. K. Benzylidene rhodanines as novel inhibitors of UDP-N-acetylmuramate/L-alanine ligase Bioorg. Med. Chem. Lett. 2002, 12 (4) 697-699 10.1016/S0960-894X(01)00832-0
16. Hu, Y.; Helm, J. S.; Chen, L.; Ginsberg, C.; Gross, B.; Kraybill, B.; Tiyanont, K.; Fang, X.; Wu, T.; Walker, S. Identification of selective inhibitors for the glycosyltransferase MurG via high-throughput screening Chem. Biol. 2004, 11, 703-711 10.1016/j.chembiol.2004.02.024
17. Zervosen, A.; Lu, W. P.; Chen, Z.; White, R. E.; Demuth, T. P., Jr.; Frere, J. M. Interactions between penicillin-binding proteins (PBPs) and two novel classes of PBP inhibitors, arylalkylidene rhodanines and arylalkylidene iminothiazolidin-4-ones Antimicrob. Agents Chemother. 2004, 48, 961-969 10.1128/AAC.48.3.961-969.2004
18. Grant, E. B.; Guiadeen, D.; Baum, E. Z.; Foleno, B. D.; Jin, H.; Montenegro, D. A.; Nelson, E. A.; Bush, K.; Hlasta, D. J. The synthesis and SAR of rhodanines as novel class C beta-lactamase inhibitors Bioorg. Med. Chem. Lett. 2000, 10, 2179-2182 10.1016/S0960-894X(00)00444-3
19. Mariner, K. R.; Trowbridge, R.; Agarwal, A. K.; Miller, K.; O'Neill, A. J.; Fishwick, C. W.; Chopra, I. Furanyl-rhodanines are unattractive drug candidates for development as inhibitors of bacterial RNA polymerase Antimicrob. Agents Chemother. 2010, 54, 4506-4509 10.1128/AAC.00753-10
20. Shi, S.; Ehrt, S. Dihydrolipoamide acyltransferase is critical for Mycobacterium tuberculosis pathogenesis Infect. Immun. 2006, 74, 56-63 10.1128/IAI.74.1.56-63.2006
21. Johnson, S. L.; Jung, D.; Forino, M.; Chen, Y.; Satterthwait, A.; Rozanov, D. V.; Strongin, A. Y.; Pellecchia, M. Anthrax lethal factor protease inhibitors: synthesis, SAR, and structure-based 3D QSAR studies J. Med. Chem. 2006, 49, 27-30 10.1021/jm050892j
22. Johnson, S. L.; Chen, L. H.; Harbach, R.; Sabet, M.; Savinov, A.; Cotton, N. J.; Strongin, A.; Guiney, D.; Pellecchia, M. Rhodanine derivatives as selective protease inhibitors against bacterial toxins Chem. Biol. Drug Des. 2008, 71, 131-139 10.1111/j.1747-0285.2007.00617.x
23. Ge, X.; Wakim, B.; Sem, D. S. Chemical proteomics-based drug design: target and antitarget fishing with a catechol-rhodanine privileged scaffold for NAD(P)(H) binding proteins J. Med. Chem. 2008, 51, 4571-4580 10.1021/jm8002284
24. Kumar, G.; Parasuraman, P.; Sharma, S. K.; Banerjee, T.; Karmodiya, K.; Surolia, N.; Surolia, A. Discovery of a rhodanine class of compounds as inhibitors of Plasmodium falciparum enoyl-acyl carrier protein reductase J. Med. Chem. 2007, 50, 2665-2675 10.1021/jm061257w
25. Cambridge Crystallographic Data Centre. In http://www.ccdc.cam.ac.uk/Solutions/GoldSuite/pages/GoldSuite.aspx.
26. Song, M. X.; Zheng, C. J.; Deng, X. Q.; Wang, Q.; Hou, S. P.; Liu, T. T.; Xing, X. L.; Piao, H. R. Synthesis and bioactivity evaluation of rhodanine derivatives as potential anti-bacterial agents Eur. J. Med. Chem. 2012, 54, 403-412 10.1016/j.ejmech.2012.05.023
27. Froquet, R.; Lelong, E.; Marchetti, A.; Cosson, P. Dictyostelium discoideum: a model host to measure bacterial virulence Nat. Protoc. 2008, 4, 25-30 10.1038/nprot.2008.212
28. Reich-Slotky, R.; Kabbash, C. A.; Della-Latta, P.; Blanchard, J. S.; Feinmark, S. J.; Freeman, S.; Kaplan, G.; Shuman, H. A.; Silverstein, S. C. Gemfibrozil inhibits Legionella pneumophila and Mycobacterium tuberculosis enoyl coenzyme A reductases and blocks intracellular growth of these bacteria in macrophages J. Bacteriol. 2009, 191, 5262-5271 10.1128/JB.00175-09
29. Harrison, C. F.; Kicka, S.; Trofimov, V.; Berschl, K.; Ouertatani-Sakouhi, H.; Ackermann, N.; Hedberg, C.; Cosson, P.; Soldati, T.; Hilbi, H. Exploring anti-bacterial compounds against intracellular Legionella PLoS One 2013, 8, e74813 10.1371/journal.pone.0074813
30. Luckner, S. R.; Liu, N.; Am Ende, C. W.; Tonge, P. J.; Kisker, C. A slow, tight binding inhibitor of InhA, the enoyl-acyl carrier protein reductase from Mycobacterium tuberculosis J. Biol. Chem. 2010, 285, 14330-14337 10.1074/jbc.M109.090373
31. Parikh, S.; Moynihan, D. P.; Xiao, G.; Tonge, P. J. Roles of tyrosine 158 and lysine 165 in the catalytic mechanism of InhA, the enoyl-ACP reductase from Mycobacterium tuberculosis Biochemistry 1999, 38, 13623-13634 10.1021/bi990529c
32. Kuo, M. R.; Morbidoni, H. R.; Alland, D.; Sneddon, S. F.; Gourlie, B. B.; Staveski, M. M.; Leonard, M.; Gregory, J. S.; Janjigian, A. D.; Yee, C.; Musser, J. M.; Kreiswirth, B.; Iwamoto, H.; Perozzo, R.; Jacobs, W. R., Jr.; Sacchettini, J. C.; Fidock, D. A. Targeting tuberculosis and malaria through inhibition of Enoyl reductase: compound activity and structural data J. Biol. Chem. 2003, 278, 20851-20859 10.1074/jbc.M211968200
33. SYBYL-X 2.1.1; Tripos International: 1699 South Hanley Road, St. Louis, Missouri, 63144, USA; http://www.certara.com/.
34. Maestro; Schrödinger Inc.: Cambridge, MA 02142, 2013; www.Schrodinger.com.
35. Andreu, N.; Zelmer, A.; Sampson, S. L.; Ikeh, M.; Bancroft, G. J.; Schaible, U. E.; Wiles, S.; Robertson, B. D. Rapid in vivo assessment of drug efficacy against Mycobacterium tuberculosis using an improved firefly luciferase J. Antimicrob. Chemother. 2013, 68, 2118-2127 10.1093/jac/dkt155
36. Tiaden, A. N.; Kessler, A.; Hilbi, H. Analysis of legionella infection by flow cytometry Methods Mol. Biol. 2013, 954, 233-249 10.1007/978-1-62703-161-5-14
37. Tiaden, A.; Spirig, T.; Weber, S. S.; Bruggemann, H.; Bosshard, R.; Buchrieser, C.; Hilbi, H. The Legionella pneumophila response regulator LqsR promotes host cell interactions as an element of the virulence regulatory network controlled by RpoS and LetA Cell. Microbiol. 2007, 9, 2903-2920 10.1111/j.1462-5822.2007.01005.x
38. Wiegand, I.; Hilpert, K.; Hancock, R. E. Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances Nat. Protoc. 2008, 3, 163-175 10.1038/nprot.2007.521
39. Eloff, J. N. A sensitive and quick microplate method to determine the minimal inhibitory concentration of plant extracts for bacteria Planta Med. 1998, 64, 711-713 10.1055/s-2006-957563
40. Kaminskyy, D.; Zimenkovsky, B.; Lesyk, R. Synthesis and in vitro anticancer activity of 2,4-azolidinedione-acetic acids derivatives Eur. J. Med. Chem. 2009, 44, 3627-3636 10.1016/j.ejmech.2009.02.023
41. Humphrey, W.; Dalke, A.; Schulten, K. VMD: visual molecular dynamics J. Mol. Graphics 1996, 14, 33-38 10.1016/0263-7855(96)00018-5
42. Wolber, G.; Langer, T. LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters J. Chem. Inf. Model. 2005, 45, 160-169 10.1021/ci049885e